PMV Pharmaceuticals financials
$1.43+5.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$18.9M | -$19.0M | -$19.2M | -$22.5M | -$22.9M | -$21.6M | -$25.2M | -$21.9M | -$20.2M | -$18.2M | -$18.9M | -$19.6M |
| Net income | -$18.1M | -$18.0M | -$18.0M | -$21.1M | -$21.2M | -$17.4M | -$23.0M | -$19.2M | -$1.2M | -$15.3M | -$15.8M | -$16.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.34 | $-0.34 | $-0.34 | $-0.40 | $-0.41 | $-0.34 | $-0.44 | $-0.37 | $-0.02 | $-0.30 | $-0.31 | $-0.34 |
| EBITDA | -$18.9M | -$19.0M | -$19.2M | -$22.5M | -$22.8M | -$21.5M | -$25.1M | -$21.5M | -$19.8M | -$17.9M | -$18.9M | -$19.3M |
| Operating cash flow | -$14.6M | -$19.7M | -$17.2M | -$19.8M | -$18.3M | -$18.3M | -$16.7M | -$16.8M | -$1.6M | -$16.2M | -$12.1M | -$15.7M |
| Free cash flow | -$14.6M | -$19.7M | -$17.2M | -$19.8M | -$18.3M | -$18.3M | -$16.7M | -$16.8M | -$1.6M | -$16.8M | -$12.3M | -$15.7M |
| Diluted shares | 53.4M | 53.3M | 53.2M | 53.0M | 52.0M | 52.0M | 51.8M | 51.6M | 51.5M | 51.4M | 51.4M | 49.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.5M | $39.1M | $38.0M | $36.3M | $44.1M | $51.3M |
| Short-term investments | $67.0M | $54.4M | $75.0M | $92.9M | $98.1M | $109.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $82.1M | $96.6M | $116.6M | $133.8M | $152.9M | $170.6M |
| Total liabilities | $10.6M | $8.6M | $11.8M | $12.8M | $12.3M | $10.5M |
| Shareholders' equity | $71.5M | $88.0M | $104.7M | $121.0M | $140.6M | $160.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology